Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'‑deoxy‑3'‑[18F] fluorothymidine in patients with lung cancer Corrigendum in /10.3892/ol.2018.8756

Wang,Xiangcheng; He,Yulin; Zhou,Weina; Bai,Xia; Wu,Yiwei; Wang,Xuemei; Li,Xiao‑Feng

doi:10.3892/ol.2017.6840

November-2017 Volume 14 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

November-2017 Volume 14 Issue 5

Full Size Image

Article Open Access

Mismatched intratumoral distribution of [18F] fluorodeoxyglucose and 3'‑deoxy‑3'‑[18F] fluorothymidine in patients with lung cancer

Corrigendum in: /10.3892/ol.2018.8756

Authors:
- Xiangcheng Wang
- Yulin He
- Weina Zhou
- Xia Bai
- Yiwei Wu
- Xuemei Wang
- Xiao‑Feng Li
View Affiliations / Copyright

Affiliations: Department of Nuclear Medicine, Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia 010050, P.R. China, Department of Nuclear Medicine, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215000, P.R. China, Department of Diagnostic Radiology, University of Louisville School of Medicine, Louisville, KY 40202, USA

Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
Pages: 5279-5284
|
Published online on: August 28, 2017

https://doi.org/10.3892/ol.2017.6840
Expand metrics +

Abstract

In a mouse model of human lung cancer, intratumoral distribution between 3'‑deoxy‑3'‑[18F] fluorothymidine (18F‑FLT) and [18F] fluorodeoxyglucose (18F‑FDG) was mutually exclusive. 18F‑FLT primarily accumulated in proliferating cancer cells, whereas 18F‑FDG accumulated in hypoxic cancer cells. The aim of the present study was to evaluate these preclinical findings in patients with lung cancer. A total of 55 patients with solitary pulmonary lesion were included in the present study. Patients underwent 18F‑FLT positron emission tomography‑computed tomography (PET/CT) and 18F‑FDG PET/CT scan with a 3‑day interval. The final diagnosis was based on histological examination. Among the 55 cases, a total of 24 cases were confirmed as malignant lesions. Mismatched 18F‑FLT‑ and 18F‑FDG‑accumulated regions were observed in 19 cases (79%) and matched in 5 (21%). Among the 31 benign lesions, 18F‑FLT and 18F‑FDG were mismatched in 12 cases (39%) and matched in 19 (61%). The difference in intratumoral distribution of 18F‑FLT and 18F‑FDG between malignant and benign lesions was statistically significant (P<0.05). The results of the present study indicate that a mismatch in intratumoral distribution of 18F‑FLT and 18F‑FDG may be a feature of patients with lung cancer. Increased 18F‑FDG accumulation may serve as an indicator of tumor hypoxia, whereas regions with increased 18F‑FLT uptake may be associated with an increased rate of cancer cell proliferation in patients with lung cancer.

View Figures

View References

1	Herrmann K, Erkan M, Dobritz M, Schuster T, Siveke JT, Beer AJ, Wester HJ, Schmid RM, Friess H, Schwaiger M, et al: Comparison of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography (FLT PET) and FDG PET/CT for the detection and characterization of pancreatic tumours. Eur J Nucl Med Mol Imaging. 39:846–851. 2012. View Article : Google Scholar : PubMed/NCBI
2	Nakajo M, Nakajo M, Kajiya Y, Jinguji M, Mori S, Aridome K, Suenaga T and Tanaka S: High FDG and low FLT Uptake in a thyroid papillary carcinoma incidentally discovered by FDG PET/CT. Clin Nucl Med. 37:607–608. 2012. View Article : Google Scholar : PubMed/NCBI
3	Zander T, Scheffler M, Nogova L, Kobe C, Engel-Riedel W, Hellmich M, Papachristou I, Toepelt K, Draube A, Heukamp L, et al: Early prediction of nonprogression in advanced non-small-cell lung cancer treated with erlotinib by using [(18)F]fluorodeoxyglucose and [(18)F]fluorothymidine positron emission tomography. J Clin Oncol. 29:1701–1708. 2011. View Article : Google Scholar : PubMed/NCBI
4	Frings V, de Langen AJ, Smit EF, van Velden FH, Hoekstra OS, van Tinteren H and Boellaard R: Repeatability of metabolically active volume measurements with 18F-FDG and 18F-FLT PET in non-small cell lung cancer. J Nucl Med. 51:1870–1877. 2010. View Article : Google Scholar : PubMed/NCBI
5	Yang W, Zhang Y, Fu Z, Yu J, Sun X, Mu D and Han A: Imaging of proliferation with 18F-FLT PET/CT versus 18F-FDG PET/CT in non-small-cell lung cancer. Eur J Nucl Med Mol Imaging. 37:1291–1299. 2010. View Article : Google Scholar : PubMed/NCBI
6	Yamamoto Y, Nishiyama Y, Ishikawa S, Nakano J, Chang SS, Bandoh S, Kanaji N, Haba R, Kushida Y and Ohkawa M: Correlation of 18F-FLT and 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 34:1610–1616. 2007. View Article : Google Scholar : PubMed/NCBI
7	Buck AK, Halter G, Schirrmeister H, Kotzerke J, Wurziger I, Glatting G, Mattfeldt T, Neumaier B, Reske SN and Hetzel M: Imaging proliferation in lung tumors with PET: 18F-FLT versus 18F-FDG. J Nucl Med. 44:1426–1431. 2003.PubMed/NCBI
8	Burgman P, O'Donoghue JA, Humm JL and Ling CC: Hypoxia-induced increase in FDG uptake in MCF7 cells. J Nucl Med. 42:170–175. 2001.PubMed/NCBI
9	Pugachev A, Ruan S, Carlin S, Larson SM, Campa J, Ling CC and Humm JL: Dependence of FDG uptake on tumor microenvironment. Int J Radiat Oncol Biol Phys. 62:545–553. 2005. View Article : Google Scholar : PubMed/NCBI
10	Li XF, Ma Y, Sun X, Humm JL, Ling CC and O'Donoghue JA: High 18F-FDG uptake in microscopic peritoneal tumors requires physiologic hypoxia. J Nucl Med. 51:632–638. 2010. View Article : Google Scholar : PubMed/NCBI
11	Dence CS, Ponde DE, Welch MJ and Lewis JS: Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer. Nucl Med Biol. 35:713–720. 2008. View Article : Google Scholar : PubMed/NCBI
12	Mudd SR, Holich KD, Voorbach MJ, Cole TB, Reuter DR, Tapang P, Bukofzer G, Chakravartty A, Donawho CK, Palma JP, et al: Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model. Mol Imaging Biol. 14:617–624. 2012. View Article : Google Scholar : PubMed/NCBI
13	Huang T, Civelek AC, Li J, Jiang H, Ng CK, Postel GC, Shen B and Li XF: Tumor microenvironment-dependent 18F-FDG, 18F-fluorothymidine, and 18F-misonidazole uptake: A pilot study in mouse models of human non-small cell lung cancer. J Nucl Med. 53:1262–1268. 2012. View Article : Google Scholar : PubMed/NCBI
14	Li XF, Huang T, Jiang H, Wang X, Shen B, Wang X, Ng CK, Postel GC and Civelek AC: Combined injection of (18)F-fluorodeoxyglucose and 3′-Deoxy-3′-[(18)F]fluorothymidine PET achieves more complete identification of viable lung cancer cells in mice and patients than individual radiopharmaceutical: A proof-of-concept study. Transl Oncol. 6:775–783. 2013. View Article : Google Scholar : PubMed/NCBI
15	Li XF, Du Y, Ma Y, Postel GC and Civelek AC: (18)F-fluorodeoxyglucose uptake and tumor hypoxia: Revisit (18)F-fluorodeoxyglucose in oncology application. Transl Oncol. 7:240–247. 2014. View Article : Google Scholar : PubMed/NCBI
16	Zhang G, Li J, Wang X, Ma Y, Yin X, Wang F, Zheng H, Duan X, Postel GC and Li XF: The reverse Warburg effect and 18F-FDG uptake in non-small cell lung cancer A549 in mice: A pilot study. J Nucl Med. 56:607–612. 2015. View Article : Google Scholar : PubMed/NCBI
17	Bunyaviroch T and Coleman RE: PET evaluation of lung cancer. J Nucl Med. 47:451–469. 2006.PubMed/NCBI
18	Graves EE, Maity A and Le QT: The tumor microenvironment in non-small-cell lung cancer. Semin Radiat Oncol. 20:156–163. 2010. View Article : Google Scholar : PubMed/NCBI
19	Vesselle H, Grierson J, Muzi M, Pugsley JM, Schmidt RA, Rabinowitz P, Peterson LM, Vallières E and Wood DE: In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: Correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res. 8:3315–3323. 2002.PubMed/NCBI
20	Tian J, Yang X, Yu L, Chen P, Xin J, Ma L, Feng H, Tan Y, Zhao Z and Wu W: A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3′-deoxy-3′-18F-fluorothymidine and 18F-FDG. J Nucl Med. 49:186–194. 2008. View Article : Google Scholar : PubMed/NCBI
21	van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, de Vries EF, Jager PL, Hoekstra HJ and Elsinga PH: Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 45:695–700. 2004.PubMed/NCBI
22	Grierson JR and Shields AF: Radiosynthesis of 3′-deoxy-3′-[(18)F]fluorothymidine: [(18)F]FLT for imaging of cellular proliferation in vivo. Nucl Med Biol. 27:143–156. 2000. View Article : Google Scholar : PubMed/NCBI
23	Tarkin JM, Joshi FR and Rudd JH: PET imaging of inflammation in atherosclerosis. Nat Rev Cardiol. 11:443–457. 2014. View Article : Google Scholar : PubMed/NCBI
24	Higashi K, Ueda Y, Seki H, Yuasa K, Oguchi M, Noguchi T, Taniguchi M, Tonami H, Okimura T and Yamamoto I: Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med. 39:1016–1020. 1998.PubMed/NCBI
25	Kurdziel K, Ravizzini G, Croft B, Tatum J, Choyke P and Kobayashi H: The evolving role of nuclear molecular imaging in cancer. Expert Opin Med Diagn. 2:829–842. 2008. View Article : Google Scholar : PubMed/NCBI
26	Wang X, Wang X, Zhao Z and Li XF: The mismatched intratumoral distribution of ¹⁸F-FLT and ¹⁸F-FDG may be a better indicator of malignancy: A PET/CT study in patients with solitary pulmonary nodule. J Nucl Med. 56 Suppl 3:S1242015.